Autologous transplantation of CD133 selected hematopoietic progenitor cells for treatment of relapsed acute lymphoblastic leukemia.

Published

Journal Article

A 21-year-old white male with relapsed acute lymphoblastic leukemia (ALL) developed an invasive Zygomycosis infection 3 weeks after beginning re-induction chemotherapy. Because of the high risk of fatal recurrence of the fungal infection, neither long-term maintenance chemotherapy nor allogeneic hematopoietic stem cell transplant (HSCT) was considered appropriate. Because his ALL blasts expressed CD34 but lacked CD133, he received a CD133 selected autologous graft following high-dose consolidation chemotherapy. The patient survives in remission 19 months after HSCT.

Full Text

Duke Authors

Cited Authors

  • Barfield, RC; Hale, GA; Burnette, K; Behm, FG; Knapp, K; Eldridge, P; Handgretinger, R

Published Date

  • March 2007

Published In

Volume / Issue

  • 48 / 3

Start / End Page

  • 349 - 353

PubMed ID

  • 16302216

Pubmed Central ID

  • 16302216

Electronic International Standard Serial Number (EISSN)

  • 1545-5017

International Standard Serial Number (ISSN)

  • 1545-5009

Digital Object Identifier (DOI)

  • 10.1002/pbc.20687

Language

  • eng